Abstract
Osteoid osteoma (OO) is one of the most common benign bone tumors with specific clinical and radiological characteristics. Analgesic therapy and surgical treatment have been considered the only therapy for a long time. Recently, safe and effective new therapeutic options have been introduced, among which percutaneous thermal ablation techniques. This review aims to describe the recent updates in the field of percutaneous thermal ablation techniques in the treatment of OO, assessing the outcomes in terms of efficacy, complications, and recurrence rate.
Highlights
Osteoid osteomas (OO) are common benign bone tumors, representing 3% of all primary bone tumors [1]
Clinical presentation often includes bone pain which is stronger at night and is associated with a significant pain relief after the use of nonsteroidal anti-inflammatory drugs (NSAIDs)
The gold standard treatment has been represented for a long time by surgical resection for those patients suffering from severe pain, who did not benefit from conservative treatment or could not tolerate long-term NSAIDs therapy [2]
Summary
Osteoid osteomas (OO) are common benign bone tumors, representing 3% of all primary bone tumors [1]. CA might have additional benefits in comparison with RF, as described in a study that assessed clinical outcomes of different techniques used for treatment of bone metastases, showing a significant reduction in pain, better medical therapy management with a decrease in opioid drugs use and shorter hospitalization times in patients treated by CA in comparison with RFA. The procedure is considered effective and successful when, in the period following the thermal ablation, the nidus of OO is replaced by a necrotic core [26] In this phase, associated signs of inflammation of the adjacent bone may be observed, as well as hyperemia and edema with ring-like appearance around the treated lesion [26]. MRI is useful to assess post-procedural complications, for example adjacent soft tissues lesions or osteompyaetliietnists[3an1]d. wThase rreedsuucletsd oinf ptheercouthtaenr e4o6%us; tRhFeApefroilrestiroenaatml ineflnat mofmOatOor,yarseraecptionrtewdasin the litesriagtnuifirecasntutlydireesd,uacreedsiunm76m%aorifztehde pinattiehnetsTaanbdled1is.appeared in 24% [27]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
